Cytel, a multinational statistical software developer and clinical research organization, recently released their Global Coronavirus COVID-19 Clinical Trial Tracker. Developed from data provided by the WHO International Clinical Trials Registry Platform (ICTRP), this web page keeps track of all interventional trials investigating COVID treatments or vaccines to date. To ensure that the statistics remain up to date, Cytel reviews the registered trials on clinicaltrials.gov daily and the trials on the European, German and Iranian Clinical Trials Registries once or twice weekly.
In the center of the dashboard, users have access to an interactive map that shows the global distribution of COVID trials. By clicking on a specific area, indicated by a green circle, you can see the number of trials taking place there, the number of involved sites and the specifications for those trials (e.g. blinding, COVID status, patient setting, treatments and expected enrollment range).
To date, there are 665 COVID treatment and vaccine trials, and that number is still climbing. Below is a snapshot of those studies, filtered by trial status.
Trial Status Globally United States & Canada Actively Recruiting 379 76 (US: 66, Canada 12) Completed 14 0 Completed with Results/Published 8 0 Not Recruiting/In Planning 257 38 (US: 34, Canada: 5) Suspended 4 0 Unclear 3 0
Focusing on the United States, there are 66 studies (phases 1 and 2) actively recruiting participants. Out of the 66 trials, 64 of them are investigating potential treatments for COVID and the remaining two are vaccine trials.
Based on a review of the inclusion criteria for treatment studies, the majority require participants to have a positive test for COVID (either by polymerase chain reaction [PCR], swab or another commercialized tool). Given that access to test kits is still highly variable between states, institutions and medical specialties, it is likely that the majority of treatment trials will take place in hospitals (intensive care units, emergency departments) and urgent care facilities. It is also important to note that even if the study protocol allows for treatment to occur in outpatient settings, many of the treatments being explored are not readily available to them.
In the upcoming months, the industry may see larger research institutions and hospitals redirect resources to COVID treatment trials and simultaneously ramp down clinical research for other indications. Research sites should be on the lookout for opportunities to onboard additional studies such as those that are discontinued by hospitals. Some experts from Nuventra and Celerion suggest that sites should consider partnering with hospitals or urgent care facilities to continue data collection for non-COVID research.
While smaller, individual research sites may not be able to take part in the first wave of COVID treatment studies, they should utilize tools such as The Global Coronavirus COVID-19 Clinical Trial Tracker to identify vaccine and treatment trials as they come down the pipeline.
To view Cytel’s Global Coronavirus COVID-19 Clinical Trial Tracker, visit www.covid-trials.org.